If a threshold of 10% risk of COPD was used to make spirometry referrals, the addition of the polygenic risk score correctly ...

Waterland Private Equity has partnered with Lavollée, Firmalis and Sipa A Ch Berthier to form the Specialty Ingredients ...

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Verona Pharma (VRNA) to $60 from $42 and keeps a Buy rating on the ...

Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

The Harvard Center for International Development (CID) is a research center working across the University and a global network of researchers and practitioners to build an international pool of talent ...

Friday - Shares of Verona Pharma (NASDAQ:VRNA) received a positive outlook from Roth/MKM as the firm initiated coverage with a Buy rating and a 12-month price target of $68. The bullish stance is ...

As of December 23, 2024, the average one-year price target for Verona Pharma plc - Depositary Receipt is $47.94/share. The forecasts range from a low of $36.36 to a high of $67.20.

Please Note: All times UK. Tables are subject to change. The BBC is not responsible for any changes that may be made. Manager: Paolo Zanetti Formation: 3 - 4 - 1 - 2 Manager: Kosta Runjaic ...

Verona Pharma stock opened at $45.20 on Wednesday. The business has a 50 day moving average of $41.33 and a 200-day moving average of $31.52. The company has a market capitalization of $3.64 ...